Medicare proposes change in anemia drug usage (Reuters)
Reuters – The Medicare federal health insurance program has proposed removing its requirement that kidney dialysis providers keep patient hemoglobin levels above a set minimum, which could lead to lower use of Epogen, the anemia drug sold by Amgen.
View full post on Yahoo! News: Health News
Leave a Reply